Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.

已取消 20 由 karry 发布于 2026/7/2 15:07:15

DOI:10.1016/S1470-2045(18)30576-X
作者：Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M Voorhees, Brandi Reeves, Edward N Libby, Paul G Richardson, Larry D Anderson, Heather J Sutherland,&nbs
文献类型：期刊论文
补充材料：仅需补充材料
文献链接：https://doi.org/10.1016/S1470-2045(18)30576-X
管理员驳回:该文件为官网显示的版本，请提供完整版 Supplement PDF链接

Elsevier

Abstract：Background: B-cell maturation antigen (BCMA) is a cell-surface receptor of the tumour necrosis superfamily required for plasma cell survival. BMCA is universally detected on patient-derived

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SageThe Effect of Attachment Priming on State Attachment Security in Middle Childhood: The Moderating Roles of Trait Attachment and State Attachment Volatility